首页 > 最新文献

Journal of Pharmaceutical Health Care and Sciences最新文献

英文 中文
Induction of CYP3A activity by dexamethasone may not be strong, even at high doses: insights from a case of tacrolimus co-administration. 地塞米松诱导CYP3A活性可能不强,即使在高剂量:从他克莫司共给药的情况下的见解。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-04 DOI: 10.1186/s40780-023-00310-0
Yoshiyuki Ohno, Toyohito Oriyama, Akira Honda, Mineo Kurokawa, Tappei Takada

Background: Dexamethasone (DEX) induces CYP3A activity in a concentration-dependent manner. However, no study has examined changes in the blood concentration of CYP3A substrate drugs when DEX is administered at high doses. Herein, we present a case in which tacrolimus (TAC), a typical CYP3A substrate drug, was co-administered with a chemotherapy regimen that included high-dose DEX.

Case presentation: A 71-year-old woman underwent liver transplantation for hepatocellular carcinoma 18 years prior to her inclusion in this case study. She was receiving TAC orally at 2 mg/day and had a stable trough blood concentration of approximately 4 ng/mL and a trough blood concentration/dose (C/D) ratio of approximately 2. The patient was diagnosed with post-transplant lymphoproliferative disease (histological type: Burkitt's lymphoma) after admission. Thereafter, the patient received cyclophosphamide-prednisolone (CP), followed by two courses of R-HyperCVAD (rituximab, cyclophosphamide, doxorubicin, vincristine, and DEX) and R-MA (rituximab, methotrexate, and cytarabine) replacement therapy. DEX (33 mg/day) was administered intravenously on days 1-4 and days 11-14 of R-HyperCVAD treatment, and aprepitant (APR) was administered on days 1-5 in both courses. The TAC C/D ratio decreased to approximately 1 on day 11 during both courses, and then increased. Furthermore, a decreasing trend in the TAC C/D ratio was observed after R-MA therapy. The decrease in the TAC C/D ratio was attributed to APR administration rather than to DEX.

Conclusion: The induction of CYP3A activity by a high dose of DEX may not be strong. The pharmacokinetic information on DEX and in vitro enzyme activity induction studies also suggested that CYP3A activity induction is not prominent under high-dose DEX treatment.

背景:地塞米松(DEX)以浓度依赖的方式诱导CYP3A活性。然而,尚无研究考察高剂量给药DEX时CYP3A底物药物血药浓度的变化。在这里,我们提出了一个病例,他克莫司(TAC),一种典型的CYP3A底物药物,与化疗方案,包括大剂量的DEX共同施用。病例介绍:一名71岁的女性在纳入本病例研究前18年因肝细胞癌接受了肝移植。患者口服TAC 2 mg/天,稳定血药谷浓度约为4 ng/mL,血药谷浓度/剂量(C/D)比约为2。患者入院后被诊断为移植后淋巴增生性疾病(组织学类型:伯基特淋巴瘤)。此后,患者接受环磷酰胺-泼尼松龙(CP)治疗,随后接受两个疗程的R-HyperCVAD(利妥昔单抗、环磷酰胺、阿霉素、长春新碱和右美右咪啶)和R-MA(利妥昔单抗、甲氨喋呤和阿糖胞苷)替代治疗。在R-HyperCVAD治疗的第1-4天和第11-14天静脉滴注DEX (33 mg/天),在两个疗程的第1-5天静脉滴注阿瑞吡坦(APR)。两疗程的TAC C/D比值均在第11天降至1左右,随后又升高。此外,R-MA治疗后TAC C/D比值呈下降趋势。TAC C/D比值的降低归因于APR的使用,而不是DEX。结论:大剂量DEX对CYP3A活性的诱导作用可能不强。DEX的药代动力学信息和体外酶活性诱导研究也表明,大剂量DEX对CYP3A活性的诱导不显著。
{"title":"Induction of CYP3A activity by dexamethasone may not be strong, even at high doses: insights from a case of tacrolimus co-administration.","authors":"Yoshiyuki Ohno, Toyohito Oriyama, Akira Honda, Mineo Kurokawa, Tappei Takada","doi":"10.1186/s40780-023-00310-0","DOIUrl":"10.1186/s40780-023-00310-0","url":null,"abstract":"<p><strong>Background: </strong>Dexamethasone (DEX) induces CYP3A activity in a concentration-dependent manner. However, no study has examined changes in the blood concentration of CYP3A substrate drugs when DEX is administered at high doses. Herein, we present a case in which tacrolimus (TAC), a typical CYP3A substrate drug, was co-administered with a chemotherapy regimen that included high-dose DEX.</p><p><strong>Case presentation: </strong>A 71-year-old woman underwent liver transplantation for hepatocellular carcinoma 18 years prior to her inclusion in this case study. She was receiving TAC orally at 2 mg/day and had a stable trough blood concentration of approximately 4 ng/mL and a trough blood concentration/dose (C/D) ratio of approximately 2. The patient was diagnosed with post-transplant lymphoproliferative disease (histological type: Burkitt's lymphoma) after admission. Thereafter, the patient received cyclophosphamide-prednisolone (CP), followed by two courses of R-HyperCVAD (rituximab, cyclophosphamide, doxorubicin, vincristine, and DEX) and R-MA (rituximab, methotrexate, and cytarabine) replacement therapy. DEX (33 mg/day) was administered intravenously on days 1-4 and days 11-14 of R-HyperCVAD treatment, and aprepitant (APR) was administered on days 1-5 in both courses. The TAC C/D ratio decreased to approximately 1 on day 11 during both courses, and then increased. Furthermore, a decreasing trend in the TAC C/D ratio was observed after R-MA therapy. The decrease in the TAC C/D ratio was attributed to APR administration rather than to DEX.</p><p><strong>Conclusion: </strong>The induction of CYP3A activity by a high dose of DEX may not be strong. The pharmacokinetic information on DEX and in vitro enzyme activity induction studies also suggested that CYP3A activity induction is not prominent under high-dose DEX treatment.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"9 1","pages":"39"},"PeriodicalIF":1.0,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138477949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of patients’ thoughts and background factors influencing attitudes toward Deprescribing: interviews to obtain hints for highly satisfying and valid prescriptions 分析患者的想法和影响处方态度的背景因素:通过访谈获得高度满意和有效处方的提示
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-01 DOI: 10.1186/s40780-023-00325-7
Sayaka Arai, Takahiro Ishikawa, K. Arai, Takaaki Suzuki, Itsuko Ishii
{"title":"Analysis of patients’ thoughts and background factors influencing attitudes toward Deprescribing: interviews to obtain hints for highly satisfying and valid prescriptions","authors":"Sayaka Arai, Takahiro Ishikawa, K. Arai, Takaaki Suzuki, Itsuko Ishii","doi":"10.1186/s40780-023-00325-7","DOIUrl":"https://doi.org/10.1186/s40780-023-00325-7","url":null,"abstract":"","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" 34","pages":""},"PeriodicalIF":1.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138613991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of combined use of Suvorexant and Ramelteon in preventing postoperative delirium: a retrospective comparative study. 舒瑞芬与拉美替恩联合应用预防术后谵妄疗效的回顾性比较研究。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-01 DOI: 10.1186/s40780-023-00311-z
Shoya Ikeuchi, Rei Tanaka, Teiichi Sugiura, Kaori Shinsato, Akane Wakabayashi, Junya Sato, Keiko Suzuki, Michihiro Shino

Background: Suvorexant and ramelteon have been presented as useful for preventing postoperative delirium. Previous studies reported on the comparison with benzodiazepine hypnotics which have been known for the risk for inducing delirium, but the comparison with patients not taking any hypnotics has not been reported yet. Therefore, we assessed the incidence rates for postoperative delirium comparing cancer patients who received preoperative combined administration with suvorexant and ramelteon and those not taking any hypnotics.

Methods: Among 110 cancer patients who underwent surgeries at the Division of Hepato-Biliary-Pancreatic Surgery at the Shizuoka Cancer Center between April 1, 2017 and June 30, 2020, 50 patients who received combined administration with suvorexant and ramelteon from 7 days prior to their surgeries and 60 patients who did not take any hypnotics including suvorexant and ramelteon were classified. They were retrospectively observed during the 7 days from their surgeries onward to compare the cumulative incidence rates for postoperative delirium.

Results: The cumulative incidence rate for postoperative delirium during the 7 days in the combined-administration group was 14.0% (7/50), while that for the no-hypnotic group was 36.7% (22/60), which proved that the incidence rate for the former was significantly low (OR: 0.28, 95%CI: 0.11-0.73, P = 0.009).

Conclusions: The present study suggests that the preventive combined administration with suvorexant and ramelteon starting from the preoperative period for cancer patients can be effective in lowering the incidence rate for postoperative delirium.

Trial registration: Retrospectively registered.

背景:舒瑞芬和瑞美替恩被认为是预防术后谵妄的有效药物。以往的研究报道了与苯二氮卓类催眠药物的比较,苯二氮卓类催眠药物有引起谵妄的风险,但与未服用任何催眠药物的患者的比较尚未报道。因此,我们评估了术后谵妄的发生率,比较了术前联合使用舒瑞芬和雷美替宁的癌症患者和未使用任何催眠药物的癌症患者。方法:对2017年4月1日至2020年6月30日在静冈癌症中心肝胆胰外科接受手术的110例癌症患者进行分类,其中50例患者在手术前7天内联合服用了suvorexant和ramelteon, 60例患者未服用任何催眠药物(包括suvorexant和ramelteon)。回顾性观察手术后7天,比较术后谵妄的累积发生率。结果:联合给药组术后7 d内谵妄的累计发生率为14.0%(7/50),未给药组为36.7%(22/60),联合给药组明显低于未给药组(OR: 0.28, 95%CI: 0.11 ~ 0.73, P = 0.009)。结论:本研究提示,癌症患者术前开始预防性联合瑞美替宁和瑞福瑞特可有效降低术后谵妄的发生率。试验注册:回顾性注册。
{"title":"Efficacy of combined use of Suvorexant and Ramelteon in preventing postoperative delirium: a retrospective comparative study.","authors":"Shoya Ikeuchi, Rei Tanaka, Teiichi Sugiura, Kaori Shinsato, Akane Wakabayashi, Junya Sato, Keiko Suzuki, Michihiro Shino","doi":"10.1186/s40780-023-00311-z","DOIUrl":"10.1186/s40780-023-00311-z","url":null,"abstract":"<p><strong>Background: </strong>Suvorexant and ramelteon have been presented as useful for preventing postoperative delirium. Previous studies reported on the comparison with benzodiazepine hypnotics which have been known for the risk for inducing delirium, but the comparison with patients not taking any hypnotics has not been reported yet. Therefore, we assessed the incidence rates for postoperative delirium comparing cancer patients who received preoperative combined administration with suvorexant and ramelteon and those not taking any hypnotics.</p><p><strong>Methods: </strong>Among 110 cancer patients who underwent surgeries at the Division of Hepato-Biliary-Pancreatic Surgery at the Shizuoka Cancer Center between April 1, 2017 and June 30, 2020, 50 patients who received combined administration with suvorexant and ramelteon from 7 days prior to their surgeries and 60 patients who did not take any hypnotics including suvorexant and ramelteon were classified. They were retrospectively observed during the 7 days from their surgeries onward to compare the cumulative incidence rates for postoperative delirium.</p><p><strong>Results: </strong>The cumulative incidence rate for postoperative delirium during the 7 days in the combined-administration group was 14.0% (7/50), while that for the no-hypnotic group was 36.7% (22/60), which proved that the incidence rate for the former was significantly low (OR: 0.28, 95%CI: 0.11-0.73, P = 0.009).</p><p><strong>Conclusions: </strong>The present study suggests that the preventive combined administration with suvorexant and ramelteon starting from the preoperative period for cancer patients can be effective in lowering the incidence rate for postoperative delirium.</p><p><strong>Trial registration: </strong>Retrospectively registered.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"9 1","pages":"42"},"PeriodicalIF":1.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138460526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reduced blood glucose levels by the combination of vadadustat in an elderly patient with chronic kidney disease who was receiving mitiglinide and sitagliptin: a case report 正在接受米格列奈和西他列汀治疗的老年慢性肾病患者服用伐杜他后血糖水平降低:病例报告
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-01 DOI: 10.1186/s40780-023-00316-8
A. Takakura, Toshinori Hirai, Naomi Hamaguchi, Rika Mukohara, Kazutaka Matsumoto, Yutaka Yano, Takuya Iwamoto
{"title":"Reduced blood glucose levels by the combination of vadadustat in an elderly patient with chronic kidney disease who was receiving mitiglinide and sitagliptin: a case report","authors":"A. Takakura, Toshinori Hirai, Naomi Hamaguchi, Rika Mukohara, Kazutaka Matsumoto, Yutaka Yano, Takuya Iwamoto","doi":"10.1186/s40780-023-00316-8","DOIUrl":"https://doi.org/10.1186/s40780-023-00316-8","url":null,"abstract":"","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" 48","pages":""},"PeriodicalIF":1.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138616081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Upregulation of brain-derived neurotrophic factor by Shiikuwasha (Citrus depressa Hayata) Shiikuwasha (早田柑橘)对脑源性神经营养因子的上调作用
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-01 DOI: 10.1186/s40780-023-00309-7
Kensuke Nakajima, S. Okubo, Tomoe Ohta, T. Uto, S. Oiso
{"title":"Upregulation of brain-derived neurotrophic factor by Shiikuwasha (Citrus depressa Hayata)","authors":"Kensuke Nakajima, S. Okubo, Tomoe Ohta, T. Uto, S. Oiso","doi":"10.1186/s40780-023-00309-7","DOIUrl":"https://doi.org/10.1186/s40780-023-00309-7","url":null,"abstract":"","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" 24","pages":""},"PeriodicalIF":1.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138619872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of rapid cefpodoxime disk screening for early detection of third-generation cephalosporin resistance in Escherichia coli and Klebsiella pneumoniae bacteremia. 头孢多肟快速筛查对大肠埃希菌和肺炎克雷伯菌血症第三代头孢菌素耐药的早期检测效果。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-01 DOI: 10.1186/s40780-023-00313-x
Mikiyasu Sakai, Takamasa Sakai, Yuki Nagata, Hiroko Komai, Yoshio Miyake, Toshitaka Watariguchi, Atsushi Kawabata, Fumiko Ohtsu

Background: Several methods have been reported for detecting resistance genes or phenotypic testing on the day of positive blood culture in Escherichia coli or Klebsiella pneumoniae bacteremia. However, some facilities have not introduced these methods because of costs or other reasons. Toyota Kosei Hospital introduced cefpodoxime (CPDX) rapid screening on May 7, 2018, to enable early detection of third-generation cephalosporin resistance. In this study, we aimed to evaluate the effects of intervention with an Antimicrobial Stewardship Team using CPDX rapid screening.

Methods: Cefotaxime (CTX)-resistant E. coli or K. pneumoniae bacteremia cases were selected retrospectively and divided into two groups: the pre-CPDX screening (June 1, 2015, to May 6, 2018) and CPDX screening groups (July 7, 2018, to August 31, 2021). The primary outcome was the proportion of cases in which modifications were made to the administration of susceptible antimicrobial agents within 24 h of blood culture-positive reports.

Results: Overall, 63 patients in the pre-CPDX screening group and 84 patients in the CPDX screening group were eligible for analysis. The proportion of patients who modified to susceptible antimicrobial agents within 24 h of blood culture-positive reports was significantly increased in the CPDX screening group compared to that in the pre-CPDX screening group (6.3% vs. 22.6%, p = 0.010).

Conclusion: The results demonstrated that in CTX-resistant E. coli or K. pneumoniae bacteremia, CPDX rapid screening increased the proportion of early initiation of appropriate antimicrobial agents.

背景:在大肠埃希氏菌或肺炎克雷伯氏菌血症血培养阳性当天,已有几种检测耐药基因或表型的方法报道。然而,一些设施由于成本或其他原因而没有引入这些方法。丰田保生医院于2018年5月7日推出头孢多肟(CPDX)快速筛查,以早期发现第三代头孢菌素耐药。在这项研究中,我们旨在评估抗菌药物管理团队使用CPDX快速筛选的干预效果。方法:回顾性选择头孢噻肟(CTX)耐药大肠杆菌或肺炎克雷伯菌血症病例,分为CPDX前筛查组(2015年6月1日至2018年5月6日)和CPDX筛查组(2018年7月7日至2021年8月31日)。主要结果是在血培养阳性报告后24小时内修改敏感抗菌药物给药的病例比例。结果:总体而言,CPDX前筛查组有63例患者,CPDX筛查组有84例患者符合分析条件。CPDX筛查组在血培养阳性报告24 h内改用敏感抗菌药物的患者比例较CPDX前筛查组显著增加(6.3% vs. 22.6%, p = 0.010)。结论:结果表明,在耐ctx的大肠杆菌或肺炎克雷伯菌血症中,CPDX快速筛选可提高早期启动合适抗菌药物的比例。
{"title":"Effect of rapid cefpodoxime disk screening for early detection of third-generation cephalosporin resistance in Escherichia coli and Klebsiella pneumoniae bacteremia.","authors":"Mikiyasu Sakai, Takamasa Sakai, Yuki Nagata, Hiroko Komai, Yoshio Miyake, Toshitaka Watariguchi, Atsushi Kawabata, Fumiko Ohtsu","doi":"10.1186/s40780-023-00313-x","DOIUrl":"10.1186/s40780-023-00313-x","url":null,"abstract":"<p><strong>Background: </strong>Several methods have been reported for detecting resistance genes or phenotypic testing on the day of positive blood culture in Escherichia coli or Klebsiella pneumoniae bacteremia. However, some facilities have not introduced these methods because of costs or other reasons. Toyota Kosei Hospital introduced cefpodoxime (CPDX) rapid screening on May 7, 2018, to enable early detection of third-generation cephalosporin resistance. In this study, we aimed to evaluate the effects of intervention with an Antimicrobial Stewardship Team using CPDX rapid screening.</p><p><strong>Methods: </strong>Cefotaxime (CTX)-resistant E. coli or K. pneumoniae bacteremia cases were selected retrospectively and divided into two groups: the pre-CPDX screening (June 1, 2015, to May 6, 2018) and CPDX screening groups (July 7, 2018, to August 31, 2021). The primary outcome was the proportion of cases in which modifications were made to the administration of susceptible antimicrobial agents within 24 h of blood culture-positive reports.</p><p><strong>Results: </strong>Overall, 63 patients in the pre-CPDX screening group and 84 patients in the CPDX screening group were eligible for analysis. The proportion of patients who modified to susceptible antimicrobial agents within 24 h of blood culture-positive reports was significantly increased in the CPDX screening group compared to that in the pre-CPDX screening group (6.3% vs. 22.6%, p = 0.010).</p><p><strong>Conclusion: </strong>The results demonstrated that in CTX-resistant E. coli or K. pneumoniae bacteremia, CPDX rapid screening increased the proportion of early initiation of appropriate antimicrobial agents.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"9 1","pages":"43"},"PeriodicalIF":1.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138460525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between antihypertensive drug use and number of people with high blood pressure in FY 2018: a descriptive epidemiological study based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan open data 2018年度抗高血压药物使用与高血压患者人数之间的关系:基于日本全国健康保险索赔和特定健康检查数据库开放数据的描述性流行病学研究
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-01 DOI: 10.1186/s40780-023-00317-7
Kanako Mizuno, Ryo Inose, Yukina Yoshimura, Y. Muraki
{"title":"Relationship between antihypertensive drug use and number of people with high blood pressure in FY 2018: a descriptive epidemiological study based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan open data","authors":"Kanako Mizuno, Ryo Inose, Yukina Yoshimura, Y. Muraki","doi":"10.1186/s40780-023-00317-7","DOIUrl":"https://doi.org/10.1186/s40780-023-00317-7","url":null,"abstract":"","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"129 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138621584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bleeding risk factors and real-world antithrombotic therapies in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention: a retrospective study 接受经皮冠状动脉介入治疗的老年心房颤动患者的出血风险因素和实际抗血栓疗法:一项回顾性研究
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-01 DOI: 10.1186/s40780-023-00308-8
Kanako Fujita, Noriko Kohyama, Miki Sato, Tomokazu Deguchi, Hiroshi Suzuki, M. Ebato, Mari Kogo
{"title":"Bleeding risk factors and real-world antithrombotic therapies in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention: a retrospective study","authors":"Kanako Fujita, Noriko Kohyama, Miki Sato, Tomokazu Deguchi, Hiroshi Suzuki, M. Ebato, Mari Kogo","doi":"10.1186/s40780-023-00308-8","DOIUrl":"https://doi.org/10.1186/s40780-023-00308-8","url":null,"abstract":"","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" 24","pages":""},"PeriodicalIF":1.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138616633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recovery from indomethacin-induced gastrointestinal bleeding by treatment with teprenone. 替普孕酮治疗消炎痛致消化道出血的疗效观察。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-11-28 DOI: 10.1186/s40780-023-00312-y
Saori Deguchi, Ayusa Iwakami, Mizuki Tujigiwa, Hiroko Otake, Yu Mano, Naoki Yamamoto, Yosuke Nakazawa, Manju Misra, Noriaki Nagai

Background: Gastrointestinal injuries caused by nonsteroidal anti-inflammatory drugs (NSAIDs) is a serious side effect in patients with rheumatoid arthritis (RA). However, effective therapeutic strategies have yet to be established. In this study, we investigated the therapeutic effects of teprenone (TEP), a gastric mucosal protective drug, on NSAID-induced gastrointestinal injuries in rats with RA (AA rats).

Methods: Gastrointestinal injury was induced by oral administration of indomethacin (IMC), a typical NSAID. TEP was orally administered after IMC-induced gastrointestinal bleeding, and the stomach, jejunum, and ileum were excised.

Results: On day 14 of IMC administration, lesion areas in the stomach, jejunum, and ileum were significantly larger in AA rats than in normal rats. When TEP was orally administered to AA rats, the lesion areas in the stomach, jejunum, and ileum significantly decreased compared with those in control rats (IMC-induced AA rats). Therefore, we measured NOS2 mRNA and NO levels, which were significantly decreased in rats with IMC-induced AA after treatment with TEP.

Conclusions: These results suggest that the oral administration of TEP may be useful for the treatment of NSAID-induced gastrointestinal injuries in patients with RA.

背景:非甾体抗炎药(NSAIDs)引起的胃肠道损伤是类风湿性关节炎(RA)患者的严重副作用。然而,有效的治疗策略尚未建立。本研究探讨胃粘膜保护药物替普诺(TEP)对非甾体抗炎药(nsaid)诱导的RA大鼠(AA大鼠)胃肠道损伤的治疗作用。方法:口服典型非甾体抗炎药吲哚美辛(IMC)致胃肠道损伤。imc致胃肠道出血后口服TEP,切除胃、空肠和回肠。结果:IMC给药第14天,AA大鼠胃、空肠、回肠病变面积明显大于正常大鼠。口服TEP给药AA大鼠胃、空肠、回肠病变面积较对照组(imc诱导AA大鼠)明显减少。因此,我们测量了imc诱导AA大鼠在TEP治疗后NOS2 mRNA和NO水平显著降低。结论:这些结果提示口服TEP可能有助于治疗非甾体抗炎药引起的RA患者胃肠道损伤。
{"title":"Recovery from indomethacin-induced gastrointestinal bleeding by treatment with teprenone.","authors":"Saori Deguchi, Ayusa Iwakami, Mizuki Tujigiwa, Hiroko Otake, Yu Mano, Naoki Yamamoto, Yosuke Nakazawa, Manju Misra, Noriaki Nagai","doi":"10.1186/s40780-023-00312-y","DOIUrl":"10.1186/s40780-023-00312-y","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal injuries caused by nonsteroidal anti-inflammatory drugs (NSAIDs) is a serious side effect in patients with rheumatoid arthritis (RA). However, effective therapeutic strategies have yet to be established. In this study, we investigated the therapeutic effects of teprenone (TEP), a gastric mucosal protective drug, on NSAID-induced gastrointestinal injuries in rats with RA (AA rats).</p><p><strong>Methods: </strong>Gastrointestinal injury was induced by oral administration of indomethacin (IMC), a typical NSAID. TEP was orally administered after IMC-induced gastrointestinal bleeding, and the stomach, jejunum, and ileum were excised.</p><p><strong>Results: </strong>On day 14 of IMC administration, lesion areas in the stomach, jejunum, and ileum were significantly larger in AA rats than in normal rats. When TEP was orally administered to AA rats, the lesion areas in the stomach, jejunum, and ileum significantly decreased compared with those in control rats (IMC-induced AA rats). Therefore, we measured NOS2 mRNA and NO levels, which were significantly decreased in rats with IMC-induced AA after treatment with TEP.</p><p><strong>Conclusions: </strong>These results suggest that the oral administration of TEP may be useful for the treatment of NSAID-induced gastrointestinal injuries in patients with RA.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"9 1","pages":"44"},"PeriodicalIF":1.0,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138445090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heart failure drug classes and 30-day unplanned hospital readmission among patients with heart failure in Ethiopia. 埃塞俄比亚心力衰竭患者的心力衰竭药物分类和30天意外再入院。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-11-27 DOI: 10.1186/s40780-023-00320-y
Birhanu Ayenew, Prem Kumar, Adem Hussein, Yegoraw Gashaw, Mitaw Girma, Abdulmelik Ayalew, Beza Tadesse

Background: Drug therapy is a crucial aspect of heart failure management and has been shown to reduce morbidity and mortality in heart failure patients. However, the comparative effects of these drug classes on readmission rates have not been well studied. Therefore, the aim of this study was to examine the association between different classes of heart failure drugs and 30-day readmission rates in patients with heart failure.

Method: A multicenter, hospital-based retrospective cohort design was employed and 572 randomly selected patients with heart failure were included. Data were entered in Epi-data version 4.6 and analyzed with STATA version 17. Kaplan-Meier and log-rank tests were used to estimate and compare survival time. A Cox proportional hazard model was utilized, employing both bi-variable and multi-variable analyses, to examine the effect of predictors on the timing of unplanned hospital readmissions. The strength of the association was assessed using an adjusted hazard ratio (aHR), and statistical significance was declared for p-values < 0.05 and a 95% confidence interval (CI).

Results: In this study, a total of 151 (26.40%) heart failure patients were readmitted within 30 days of discharge. In the multivariate cox proportional hazards analysis being an age (> 65 year) (AHR: 2.34, 95%CI: 1.63, 3.37), rural in residency (AHR: 1.85, 95%CI: 1.07, 3.20), hospital stays > 7 Days (AHR: 3.68, 95%CI: 2.51,5.39), discharge with Diuretics (AHR: 2.37, 95%CI: 1.45, 3.86), and discharge with Beta-Blocker (AHR: 0.48, 95%CI: 0 0.34, 0.69) were identified as independent predictors of unplanned hospital readmission.

Conclusion: Elderly patients, being in rural areas, longer hospital stays, and discharges of patients on diuretics and not on beta-blockers were independent predictors of unplanned hospital readmission. Therefore, working on these factors will help to reduce the hazard of unplanned hospital readmissions, improve patient outcomes, and increase the efficiency of heart failure management.

背景:药物治疗是心力衰竭治疗的一个重要方面,已被证明可以降低心力衰竭患者的发病率和死亡率。然而,这些药物类别对再入院率的比较效果尚未得到很好的研究。因此,本研究的目的是研究不同类型的心力衰竭药物与心力衰竭患者30天再入院率之间的关系。方法:采用多中心、以医院为基础的回顾性队列设计,随机选取572例心力衰竭患者。数据在Epi-data版本4.6中输入,并使用STATA版本17进行分析。Kaplan-Meier检验和log-rank检验用于估计和比较生存时间。采用Cox比例风险模型,采用双变量和多变量分析来检验预测因子对非计划再入院时间的影响。使用校正风险比(aHR)评估其相关性,p值具有统计学意义。结果:在本研究中,共有151例(26.40%)心力衰竭患者在出院后30天内再次入院。在多因素cox比例风险分析中,年龄(> 65岁)(AHR: 2.34, 95%CI: 1.63, 3.37)、居住在农村(AHR: 1.85, 95%CI: 1.07, 3.20)、住院时间> 7天(AHR: 3.68, 95%CI: 2.51,5.39)、出院时使用利尿剂(AHR: 2.37, 95%CI: 1.45, 3.86)和出院时使用β受体阻滞剂(AHR: 0.48, 95%CI: 0.34, 0.69)被确定为意外再入院的独立预测因素。结论:老年患者、居住在农村地区、住院时间较长、使用利尿剂而非β受体阻滞剂的患者出院是意外再入院的独立预测因素。因此,研究这些因素将有助于减少意外再入院的危险,改善患者的预后,并提高心力衰竭管理的效率。
{"title":"Heart failure drug classes and 30-day unplanned hospital readmission among patients with heart failure in Ethiopia.","authors":"Birhanu Ayenew, Prem Kumar, Adem Hussein, Yegoraw Gashaw, Mitaw Girma, Abdulmelik Ayalew, Beza Tadesse","doi":"10.1186/s40780-023-00320-y","DOIUrl":"10.1186/s40780-023-00320-y","url":null,"abstract":"<p><strong>Background: </strong>Drug therapy is a crucial aspect of heart failure management and has been shown to reduce morbidity and mortality in heart failure patients. However, the comparative effects of these drug classes on readmission rates have not been well studied. Therefore, the aim of this study was to examine the association between different classes of heart failure drugs and 30-day readmission rates in patients with heart failure.</p><p><strong>Method: </strong>A multicenter, hospital-based retrospective cohort design was employed and 572 randomly selected patients with heart failure were included. Data were entered in Epi-data version 4.6 and analyzed with STATA version 17. Kaplan-Meier and log-rank tests were used to estimate and compare survival time. A Cox proportional hazard model was utilized, employing both bi-variable and multi-variable analyses, to examine the effect of predictors on the timing of unplanned hospital readmissions. The strength of the association was assessed using an adjusted hazard ratio (aHR), and statistical significance was declared for p-values < 0.05 and a 95% confidence interval (CI).</p><p><strong>Results: </strong>In this study, a total of 151 (26.40%) heart failure patients were readmitted within 30 days of discharge. In the multivariate cox proportional hazards analysis being an age (> 65 year) (AHR: 2.34, 95%CI: 1.63, 3.37), rural in residency (AHR: 1.85, 95%CI: 1.07, 3.20), hospital stays > 7 Days (AHR: 3.68, 95%CI: 2.51,5.39), discharge with Diuretics (AHR: 2.37, 95%CI: 1.45, 3.86), and discharge with Beta-Blocker (AHR: 0.48, 95%CI: 0 0.34, 0.69) were identified as independent predictors of unplanned hospital readmission.</p><p><strong>Conclusion: </strong>Elderly patients, being in rural areas, longer hospital stays, and discharges of patients on diuretics and not on beta-blockers were independent predictors of unplanned hospital readmission. Therefore, working on these factors will help to reduce the hazard of unplanned hospital readmissions, improve patient outcomes, and increase the efficiency of heart failure management.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"9 1","pages":"49"},"PeriodicalIF":1.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138445089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pharmaceutical Health Care and Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1